NASDAQ:SLS

Sellas Life Sciences Group Stock News

Healthcare > Biotechnology

Buy SLS

*Your capital is at risk

$8.23

-0.81 (-8.96%)

At Close: Jun 05, 2026

SELLAS Life Sciences and 3D Medicines Announce Exclusive License Agreement for Development and Commercialization of Galinpepimut-S (GPS) and GPS+ in Greater China

08:30am, Monday, 07'th Dec 2020

- SELLAS to Potentially R eceive Up To $ 202 Million, Inclusive of $7.5 Million Upfront License Fee and $ 8 Million Near-term Milestone s, plus Tiered Royalties -

SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2020 Financial Results

04:32pm, Friday, 13'th Nov 2020

- Received IM PD A pproval to C ommence E nrollment in France for P ivotal Phase 3 S tudy of G alinpepimut -S in A cute M yeloid L eukemia P atients -

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by